Edge Therapeutics Inc (NASDAQ:EDGE) insider Brian A. Leuthner sold 5,000 shares of Edge Therapeutics stock in a transaction on Wednesday, January 3rd. The stock was sold at an average price of $10.11, for a total transaction of $50,550.00. Following the transaction, the insider now directly owns 87,736 shares of the company’s stock, valued at approximately $887,010.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Edge Therapeutics Inc (NASDAQ:EDGE) traded down $0.05 on Wednesday, reaching $10.05. 96,115 shares of the company’s stock traded hands, compared to its average volume of 77,674. Edge Therapeutics Inc has a 12-month low of $7.30 and a 12-month high of $13.40. The company has a current ratio of 8.34, a quick ratio of 8.34 and a debt-to-equity ratio of 0.20. The company has a market capitalization of $310.13 and a P/E ratio of -6.44.

Edge Therapeutics (NASDAQ:EDGE) last posted its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.48) by $0.11. analysts forecast that Edge Therapeutics Inc will post -1.7 earnings per share for the current fiscal year.

A number of equities analysts recently weighed in on EDGE shares. Zacks Investment Research raised shares of Edge Therapeutics from a “sell” rating to a “buy” rating and set a $12.00 target price for the company in a research note on Monday, November 6th. BidaskClub downgraded shares of Edge Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Tuesday, December 12th.

Several hedge funds and other institutional investors have recently modified their holdings of EDGE. Voya Investment Management LLC acquired a new position in shares of Edge Therapeutics during the second quarter valued at about $106,000. Russell Investments Group Ltd. grew its holdings in shares of Edge Therapeutics by 16.9% during the second quarter. Russell Investments Group Ltd. now owns 11,959 shares of the biotechnology company’s stock valued at $123,000 after buying an additional 1,733 shares during the last quarter. Trexquant Investment LP acquired a new position in shares of Edge Therapeutics during the third quarter valued at about $130,000. State of Wisconsin Investment Board acquired a new position in shares of Edge Therapeutics during the second quarter valued at about $154,000. Finally, The Manufacturers Life Insurance Company grew its holdings in shares of Edge Therapeutics by 26.2% during the second quarter. The Manufacturers Life Insurance Company now owns 18,114 shares of the biotechnology company’s stock valued at $186,000 after buying an additional 3,764 shares during the last quarter. Hedge funds and other institutional investors own 50.26% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Insider Selling: Edge Therapeutics Inc (EDGE) Insider Sells 5,000 Shares of Stock” was originally reported by American Banking News and is the property of of American Banking News. If you are accessing this news story on another website, it was illegally copied and republished in violation of US & international copyright & trademark law. The legal version of this news story can be read at https://www.americanbankingnews.com/2018/01/03/insider-selling-edge-therapeutics-inc-edge-insider-sells-5000-shares-of-stock.html.

About Edge Therapeutics

Edge Therapeutics, Inc is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening critical care conditions. The Company’s initial product candidates target rare, acute, life-threatening neurological and other conditions.

Insider Buying and Selling by Quarter for Edge Therapeutics (NASDAQ:EDGE)

Receive News & Ratings for Edge Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edge Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.